ELEV Q1 2025 Earnings Report on 5/1/2025
As of 04/30/2025 04:00 PM Eastern
- Actual Revenue
- Expected Revenue
- Beat/Miss
- YoY Revenue Growth
- Quarter
- Date
- Time
- Conference Call Date
- Conference Call Time
What President Trump’s Executive Order 14154 means for your money
Nearly $3 trillion disappeared from the stock market on Thursday morning. According to Whitney Tilson - a former hedge fund manager who predicted the dotcom crash, the housing crisis, and the 2022 tech stock bloodbath - a little-known executive order from the President's first day in office could spark a paradigm-shift that will likely catch millions of Americans off guard.
May 1, 2025 | Stansberry Research (Ad)
Get Earnings Announcements in your inbox
Want to stay updated on the latest earnings announcements and upcoming reports for companies like Elevation Oncology? Sign up for to receive timely earnings updates on Elevation Oncology and other key companies, straight to your email.
Elevation Oncology (NASDAQ:ELEV), an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target. Its EO-3021 selectively delivers a cytotoxic payload directly to cancer cells expressing Claudin 18.2. Elevation Oncology, Inc. has a license agreement with CSPC Megalith Biopharmaceutical Co., Ltd. to develop and commercialize EO-3021. The company was formerly known as 14ner Oncology, Inc. and changed its name to Elevation Oncology, Inc. in February 2020. The company was incorporated in 2019 and is based in Boston, Massachusetts.
Earnings Tools
Latest Articles
Get 30 Days of MarketBeat All Access for Free
Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools.
